Nanobiotix annual operating cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix Operating Cash Flow Growth & History (NANO)
Nanobiotix's operating cash flow was −€33.4M for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€33.4M | −€13.9M | — |
| 2024 | 2024-12-31 | −€19.6M | −€7.1M | — |
| 2023 | 2023-12-31 | −€12.5M | €24.6M | — |
| 2022 | 2022-12-31 | −€37.1M | −€7.2M | — |
| 2021 | 2021-12-31 | −€29.9M | −€2.3M | — |
| 2020 | 2020-12-31 | −€27.5M | €13.6M | — |
| 2019 | 2019-12-31 | −€41.2M | −€15.2M | — |
| 2018 | 2018-12-31 | −€26.0M | — | — |
Nanobiotix operating cash flow trends
Over the last five fiscal years, Nanobiotix's operating cash flow decreased from −€27.5M to −€33.4M, a change of −€5.9M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
